ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients
- 1 September 2017
- journal article
- review article
- Published by Elsevier in Journal of Hepatology
- Vol. 67 (3) , 585-602
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialThe Lancet Infectious Diseases, 2016
- EASL Clinical Practice Guidelines: Liver transplantationJournal of Hepatology, 2016
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseGastroenterology, 2015
- Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virusHepatology, 2015
- Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label StudyGastroenterology, 2015
- Comparison of two non-contemporaneous HCV-liver transplant cohorts: Strategies to improve the efficacy of antiviral therapyJournal of Hepatology, 2012
- Natural History of Post-Liver Transplantation Hepatitis CLiver Transplantation, 2009
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Report of the Monothematic EASL Conference on Liver Transplantation for Viral HepatitisJournal of Hepatology, 2006
- HCV-related fibrosis progression following liver transplantation: increase in recent yearsJournal of Hepatology, 2000